What patient populations were sapropterin studies focused on?

Who Benefits from Sapropterin Research?

Sapropterin, also known as Kuvan, is a medication used to treat phenylketonuria (PKU), a genetic disorder that affects the metabolism of amino acids. Research on sapropterin has primarily focused on patients with phenylketonuria, particularly those with mild to moderate forms of the disease.

Studies have shown that sapropterin is most effective in patients with PKU who have a specific genotype, characterized by a specific mutation in the PAH gene. This genotype is associated with a higher likelihood of responding to sapropterin treatment.

Mild to Moderate PKU Patients

Sapropterin research has focused on patients with mild to moderate PKU, as they often require higher doses of the medication to achieve optimal results. These patients tend to have a better response to sapropterin compared to those with severe PKU.

Pediatric Patients

Some studies have investigated the use of sapropterin in pediatric patients with PKU. These studies have demonstrated the safety and efficacy of the medication in this population, although long-term effects may not be fully understood.

Bilateral PKU

Research has also explored the use of sapropterin in patients with bilateral PKU, a severe form of the disease characterized by the presence of both PAH enzyme activity and a specific genotype.

Patient Populations Not Tested

It is essential to note that sapropterin research has not been conducted on patients with other types of PKU, such as those with specific mutations or enzymatic deficiencies. Additionally, the medication's efficacy and safety in patients with other disorders, like hyperphenylalaninemia (HPA), have not been extensively studied.

Sources:
[1] www.drugpatentwatch.com/drug/kuvan-sapropterin-dihydrochloride (accessed: March 1, 2023)
[2] Sapropterin Dihydrochloride (Kuvan). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022504s011lbl.pdf

Sources Cited:
1. DrugPatentWatch.com
2. FDA.gov